Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immunochromatography Tests Evaluated for Detection of Novel Norovirus

By LabMedica International staff writers
Posted on 02 Aug 2015
A novel GII.17 Norovirus has emerged as a major cause of epidemic and endemic acute gastroenteritis in several countries in Asia.

From September 2014 to March 2015, 70% of all outbreaks in Guangdong and Jiangsu provinces in China were caused by a novel GII.17 virus and a similar increase in the number of infections with this novel GII.17 virus has been reported in Japan and Thailand since December 2014.

Microbiologists at Chiang Mai University (Thailand) working with colleagues from Japan, analyzed randomly selected stool samples for which there was a large quantity available—a panel of six GII.17-positive stool samples from five patients in Japan and one in Thailand in which the virus copy numbers had been quantified by real-time reverse-transcriptase polymerase chain reaction (RT-PC R) for reference values. Two of the six GII.17 stool samples tested positive by four immunochromatography (IC) kits.

To evaluate if these IC tests are able to detect these novel GII.17 noroviruses, they tested four commercial kits available in Japan: GE test Noro Nissui (Nissui Pharmaceutical Co., Ltd.; Tokyo, Japan); ImmunoCatch-Noro (Eiken Chemical Co., Ltd.; Tokyo, Japan); Quick Navi-Noro 2 (Denka Seiken Co., Ltd.; Tokyo, Japan); Quick Chaser-Noro (Mizuho Medy Co., Ltd.; Tosu City, Japan).

The six specimens tested by real-time RT-PCR demonstrated that the two samples that were positive by IC test contained high virus titers of 1.90 × 109 and 8.06 × 109 virus copies/mL. In contrast, the other four specimens that were negative in the IC test had virus titers ranging from 4.91 × 103 to 2.50 ×108 virus copies/mL. The results demonstrated that at 1:10 dilution of a virus titer equal to 1.90 × 108 copies/mL, two of three tests still showed the positive results, with a weak positive band, while at 1:100 dilution equal to virus titer 1.90 × 107 copies/mL, all three IC tests were negative. These data demonstrated that the sensitivity of the IC kits for the detection of this novel GII.17 virus was about 108 copies/mL.

The authors concluded that the tested commercial IC kits for the detection Norovirus available on the market in Japan were able to detect the novel GII.17 Norovirus, but with relatively low sensitivity. Only samples that contained more than 109 copies/mL were positive in all four IC tests. They suggest a redesign of the currently available Norovirus IC tests may be required to detect the novel GII.17 noroviruses with the same sensitivity as for the more commonly circulating norovirus genotypes. Laboratories and physicians should be aware of these findings, in particular where the novel GII.17 norovirus has been shown to be circulating.

Related Links:

Chiang Mai University
Nissui Pharmaceutical 
Eiken Chemical 



Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Aspergillus Test
REALQUALITY Aspergillus
New
Mumps Virus Test
ZEUS ELISA Mumps IgG Test System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.